Results 71 to 80 of about 328,187 (300)

Resistência do Streptococcus pneumoniae à penicilina no Hospital Universitário Polydoro Ernani de São Thiago. [PDF]

open access: yes, 2006
Trabalho de Conclusão de Curso - Universidade Federal de Santa Catarina. Curso de Medicina.
Aquino, Ariel Filipe Wuerges de
core  

Breakthrough in penicillin resistance? Streptococcus pneumoniae isolates with penicillin/cefotaxime MICs of 16 mg/L and their genotypic and geographical relatedness

open access: yes, 2008
Objectives: To phenotypically and genotypically characterize 11 strains (isolated in four different centres) exhibiting penicillin MIC of 8-32 mg/L among isolates of the SPICE project. Nine isolates were from Romania (9/162; 5.56%) and two from Poland (2/
Gracia, Matilde   +11 more
core   +1 more source

Proteasome inhibitor, ixazomib prevents topoisomerase‐I degradation and reverses irinotecan resistance in colorectal cancer

open access: yesMolecular Oncology, EarlyView.
Ixazomib inhibits proteasome‐mediated degradation of topoisomerase I induced by irinotecan, thereby restoring drug sensitivity and promoting tumor cell death in colorectal cancer. Irinotecan, a topoisomerase I (topoI) inhibitor, is widely used for colorectal cancer, but resistance remains a major clinical challenge.
Yuho Ebata   +10 more
wiley   +1 more source

Rapid Determination of Benzylpenicillin Resistance in Staphylococcus aureus Bacteraemia Model

open access: yesInfection and Drug Resistance, 2020
JeongWoo Kang,1,2 Md Akil Hossain,1 Hae-chul Park,1 Yong-sang Kim,1 Sung-won Park,1 Tae-Wan Kim2 1Veterinary Drugs & Biologics Division, Animal and Plant Quarantine Agency (APQA), Gimcheon-si, Gyeongsangbuk-do, Republic of Korea; 2Department of ...
Kang J   +5 more
doaj  

Heteroresistance to penicillin in Streptococcus pneumoniae

open access: yes, 2007
Heteroresistance to beta-lactam antibiotics has been mainly described for staphylococci, for which it complicates diagnostic procedures and therapeutic success.
Morand, Brigitte, Mühlemann, Kathrin
core   +1 more source

Developmental programmes drive cellular plasticity, disease progression and therapy resistance in lung adenocarcinoma

open access: yesMolecular Oncology, EarlyView.
This study shows that lung adenocarcinomas exploit developmental branching morphogenesis to acquire a therapy resistant basal‐like tumour cell state. This process was found to be regulated by combined TP53 loss‐of‐function and type‐I interferon signalling, identifying a novel axis for biomarker and therapeutic target discovery.
Kamila J Bienkowska   +13 more
wiley   +1 more source

Serotype distribution and antimicrobial susceptibility of group B streptococci in pregnant women: results from a Swiss tertiary centre

open access: yesSwiss Medical Weekly, 2014
OBJECTIVE: To evaluate the rates of penicillin, clindamycin and erythromycin resistance and the serotype distribution among isolates of group B streptococcus (GBS) obtained from pregnant women at the University Hospital of Bern in Switzerland.
Simone Fröhlicher   +6 more
doaj   +1 more source

Stimulator of interferon genes agonist augmented antitumor immunity of osimertinib in Egfr‐mutated lung cancer

open access: yesMolecular Oncology, EarlyView.
Combining osimertinib with the STING agonist ADU‐S100 activates innate and adaptive immunity to overcome the non‐inflamed microenvironment of Egfr‐mutant lung cancer. This combination increases NK and CD8+ T‐cell infiltration, associated with activation of the STING‐IRF3 pathway and local immunogenic cell death.
Jun Nishimura   +19 more
wiley   +1 more source

Phenotypic and Genotypic Correlates of Penicillin Susceptibility in Nontoxigenic Corynebacterium diphtheriae, British Columbia, Canada, 2015–2018

open access: yesEmerging Infectious Diseases, 2020
In 2015, the Clinical and Laboratory Standards Institute (CLSI) updated its breakpoints for penicillin susceptibility in Corynebacterium species from
Jason Zou   +8 more
doaj   +1 more source

Post Penicillin Antibiotics: From acceptance to resistance?

open access: yes, 2000
Edited transcript of a Witness Seminar held at the Wellcome Institute for the History of Medicine, in London, on 12 May 1998. First published by the Wellcome Trust, 2000. ©The Trustee of the Wellcome Trust, London, 2000.
Reynolds, LA, Tansey, EM
core  

Home - About - Disclaimer - Privacy